Of primary liver cancer using proteomics research of TCM Syndrome.docVIP

 PAGE \* MERGEFORMAT 17 Of primary liver cancer using proteomics research of TCM Syndrome [Abstract] By analyzing the status of primary liver cancer and liver cancer proteomics research TCM Syndrome-type study to examine the application of proteomics technology research the feasibility of liver cancer TCM Syndrome and methods to bring to the traditional Syndrome research new opportunities. [Keywords:] primary liver cancer proteomics Syndrome With the development of modern medicine, the human genome project completed, marking the human genome research has entered a new phase, but the genomic DNA sequence does not fully reflect the information, sufficient to describe the entire life activity, in-depth study of gene function in the implementation of those - protein appears to be very necessary, proteomics is the application of large-scale protein separation and identification technology research group of a subject protein. The occurrence of primary liver cancer is a multi-link, multi-factor complex process at the molecular level have different functional protein participation, if the liver cancer syndrome type to provide biological basis of modern medicine, it will ‘permit ‘semi-quantitative, quantitative and objective, standardization, the establishment of Western medicine and TCM micro-target links, explore the’ card ‘in substance. In this paper, the use of proteomics research TCM type of primary liver cancer to make a preliminary study. A primary liver cancer proteomics research Primary liver cancer is currently a common malignant tumors in China, one of China’s annual incidence of about 35 million, about 32 million people a year die from the disease, the new 55% of patients suffering from cancer occurred in China [1,2], serious threatens people’s health and life, has become the second cancer cause of death in China [3]. Most liver cancer is already advanced the time of diagnosis, the prognosis is poor, with a median survival of only 6 months, 3-year survi